SYRS Syros Pharmaceuticals
- 5.0700
- +0.0600+1.20%
Syros Pharmaceuticals News
Press Release: Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 07, 2024-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company commi
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Download as PDF May 07, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treat
Syros to Participate in Upcoming Investor Conferences
Download as PDF May 07, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treat
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Health care stocks were mixed late Tuesday afternoon with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) rising 0.1%. The iShares Biotechnology ETF (IBB) climbe
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also f
Syros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotene
By Denny Jacob Syros Pharmaceuticals shares rose 20% after winning Food and Drug Administration fast-track designation for its tamibarotene drug candidate in certain patients with acute myeloid leuke
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cas
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. The market value of their outstanding shares is at $230.0 million. BioSig Technologie
Syros Jumps on FDA Fast Track Tag for Leukemia Drug
Express News | Syros Receives Fast Track Designation From The FDA For Tamibarotene For The Treatment Of Newly Diagnosed Unfit AML With RARA Gene Overexpression
Syros Receives Fast Track Designation From the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML With RARA Gene Overexpression
Download as PDF April 09, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline tre
Syros Pharmaceuticals(SYRS.US) Officer Sells US$51,732.45 in Common Stock
$Syros Pharmaceuticals(SYRS.US)$ Officer Roth David sold 10,451 shares of Common Stock on Apr 3, 2024 at an average price of $4.95 for a total value of $51,732.45.Source: Announcement What is statemen
Syros Pharmaceuticals Price Target Maintained With a $13.00/Share by Piper Sandler
Syros Pharmaceuticals Price Target Maintained With a $13.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Maintains $13 Price Target
Syros Pharmaceuticals (SYRS) Receives a Buy From Piper Sandler
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Download as PDF April 02, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline tre
Express News | HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
Syros Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 183.02% HC Wainwright & Co. → $15 Reiterates Buy → Buy 10/03/2023 32.08% Piper Sandler $11 → $7
Analysis
Price Target
No Data
